Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Related Keywords

California ,United States ,San Diego ,Israel ,Tel Aviv ,San Francisco ,American ,Yvonne Naughton ,Exchange Commission ,Compugen Ltd ,Gilead Sciences ,Tel Aviv Stock Exchange ,Cancer Immunology Research ,Nasdaq ,Corporate Communications ,Compugen ,Securities Exchange ,American Association For Cancer Research ,Astrazeneca ,American Association ,Cancer Research ,Anat Cohen Dayag ,Chief Executive Officer ,Chief Scientific Officer ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Middle East ,Annual Report ,Investor Relations ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Publishing Amp Information Services ,Clinical Trials Amp Medical Discoveries ,Surveys ,Olls And Research ,